A Smart + Strong Site
Subscribe to:
POZ magazine

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


September 30, 2011

Hepatitis C in the U.S. May Be Underestimated by Over a Million

In the United States, the number of people who have been infected with hepatitis C virus (HCV) may have been undercounted by a whopping 1.1 million, according to a paper published in the September 2011 edition of Liver International. Epidemiologists believe that at least 5.2 million people in the United States are HCV antibody positive—meaning that they were infected at one time, although they may not have developed chronic hepatitis C—an increase of 1.1 million over The National Health and Nutrition Examination Survey (NHANES) estimate of 4.1 million cases.

NHANES samples American households. Because high-risk groups such as homeless people, prisoners and immigrants were not included, Eric Chak, MD, of the University of California at Los Angeles and his colleagues suggest in their paper that NHANES may have underestimated the number of HCV-positive people in the United States.

Chak’s team reviewed research on HCV rates among prisoners, homeless people, active military personnel and nursing home residents to determine a more accurate prevalence rate. They also cross-checked HCV rates among health care workers and people on long-term dialysis, because both groups are thought to have higher HCV rates than the general public, and both were underrepresented in NHANES.

NHANES reported an HCV prevalence rate of 1.6 percent among the U.S. general population. HCV rates in studies of high-risk populations varied, but they were always much higher than that of the general population. Among jailed and incarcerated individuals, HCV rates ranged from 23 percent to 41 percent, and HCV rates among homeless people ranged from 22 percent to 52 percent. Residents of nursing homes had an HCV rate of 4.5 percent.

Chak’s team found the highest HCV rates among HIV-positive veterans and homeless people, probably because of overlapping risk factors for each virus. People on active military duty were the only group with an HCV rate lower than that of the general population (0.48 percent) among those excluded from NHANES.
HCV was also more common among groups that were underrepresented in NHANES than the general population. The HCV rate among people on dialysis was 7.8 percent, and it ranged from 0.9 percent to 3.6 percent among health care workers.

When Chak and his colleagues compared the NHANES estimate of HCV among veterans and people who use injection and non-injection drugs to rates from other studies, they found that NHANES accurately reflected HCV rates among people who use drugs. However, NHANES underestimated the rate of HCV among veterans—whereas NHANES suggested a rate of 2.8 percent, Chak’s group’s review found the rate to be 5.4 percent to more than 10 percent.

Researchers arrived at their estimate by looking at the number of people in each high-risk group—which was derived from U.S. statistics—and the HCV rate in each high-risk group. Then, they added these figures to the NHANES estimate.

The authors noted that the new estimate underscores the importance of HCV prevention among high-risk groups.

Search: NHANES, hepatitis, hcv, antibody, prevalence, infection, rate, Chak, underestimated

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Conference Coverage
Health Services Directory
POZ Magazine
AIDSmeds on Twitter

Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014

7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013

more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.